# Spine QA Feedback

## Round 1/3: FAILED ($1.14)

**Issues (2):**

- [critical] Structured spine introduces a standalone 'Cholecalciferol' medication that the spec explicitly excludes. structured_spec.json line 509 lists `"Cholecalciferol (if available/tolerated)"` inside `inpatient_medication_actions_summary.continued_unless_contraindicated`. spec.md line 164 states: 'A separate vitamin D-only row is not included because vitamin D is already carried in the calcium carbonate / vitamin D combination.' The baseline_home_medication_list in the spine has exactly 19 numbered items (matching the spec) and does not contain cholecalciferol, so the entry invents a 20th medication that has no source in the world and directly contradicts the spec's stated design.
  - Suggested fix: Delete the array element `"Cholecalciferol (if available/tolerated)"` from the continued_unless_contraindicated list. Leave `"Calcium carbonate/vitamin D (if available/tolerated)"` as the only vitamin-D-containing entry, matching spec.md line 164.
- [medium] Awkward and clinically non-standard wording for the remote PCI procedure. structured_spec.json line 343 reads: `"procedure": "PCI with bare-metal-to-DES coronary stent placement (single vessel, mid-LAD)"`. 'Bare-metal-to-DES' is not a real stent category — PCI uses either a bare-metal stent (BMS) or a drug-eluting stent (DES). This wording would propagate as confusing language into WS1 (pci_stent_history_summary) and any cardiology document that cites stent type.
  - Suggested fix: Replace `"PCI with bare-metal-to-DES coronary stent placement (single vessel, mid-LAD)"` with a single stent type, e.g. `"PCI with drug-eluting coronary stent placement (single vessel, mid-LAD)"` (preferred for a 2018-09-12 placement) or `"PCI with bare-metal coronary stent placement (single vessel, mid-LAD)"`. Update the matching rationale row in /.meta/factual_decisions.md (Procedural history dates table) so the prose names the same stent type.

**Feedback given to agent:**

> Make the following two edits to /.meta/structured_spec.json:
> 
> 1) Remove the invented standalone vitamin D entry. In the `inpatient_medication_actions_summary.continued_unless_contraindicated` array (around line 509), delete the list element `"Cholecalciferol (if available/tolerated)"`. The spec (spec.md line 164) is explicit: "A separate vitamin D-only row is not included because vitamin D is already carried in the calcium carbonate / vitamin D combination." The baseline_home_medication_list has exactly 19 items (1-19) and does not include cholecalciferol; introducing it in the continued-meds list invents a medication that does not exist in the world and contradicts the spec's stated rationale. Keep the existing entry `"Calcium carbonate/vitamin D (if available/tolerated)"` unchanged.
> 
> 2) Fix the awkward PCI wording. In `procedural_history[0].procedure` (around line 343), replace `"PCI with bare-metal-to-DES coronary stent placement (single vessel, mid-LAD)"` with `"PCI with drug-eluting coronary stent placement (single vessel, mid-LAD)"` (or, if a bare-metal stent is preferred for the 2018 era, `"PCI with bare-metal coronary stent placement (single vessel, mid-LAD)"`). The 'bare-metal-to-DES' phrasing is not standard PCI terminology and would propagate as confusing language in WS1 and any downstream cardiology references. Pick one stent type and use that label consistently. If you change to BMS or DES, also update the rationale row in /.meta/factual_decisions.md (Procedural history dates table) so the rationale text matches the chosen stent type.
> 
> No other findings — every explicit spec fact (patient demographics, baseline meds, comorbidities, ICD-10s, dates, lab anchors, named providers, traps, file manifest, task parameters) is captured accurately, and the prednisone non-fixed-dose trap and inpatient-only insulin-lispro guardrail are preserved correctly.

## Round 2/3: PASSED ($0.47)
